Optimizing Biologic Agents in Ulcerative Colitis and Crohn’s Disease

被引：14
作者：
O’Toole A. [1 ]
Moss A.C. [1 ]
机构：
[1] Beth Israel Deaconess Medical Center & Harvard Medical School, 330 Brookline Avenue, Boston, 02215, MA
来源：
Current Gastroenterology Reports | 2015年 / 17卷 / 8期
关键词：
Adalimumab; Antibodies; Biologics; Crohn’s disease; Inflammatory bowel disease; Infliximab; Therapeutic drug monitoring; Trough levels; Ulcerative colitis;
D O I：
10.1007/s11894-015-0453-1
中图分类号：
学科分类号：
摘要：
The goals of therapy in inflammatory bowel disease (IBD) are the induction and maintenance of clinical and biological remission. Mucosal healing is desirable to prevent complications and reduce the need for surgery, hospitalizations, and steroid exposure. Therapeutic monoclonal antibodies (biologic agents) have revolutionized the treatment of IBD. The initial magnitude of the clinical/biologic response to these agents has been associated with a number of underlying phenotypic features in the recipient. In addition, the durability of the initial response often declines over time. This can occur due to low drug serum drug levels, anti-drug antibodies, and a shift to alternative inflammatory pathways. This review discusses strategies that may optimize the initial response to biologics and sustain this to improve patient outcomes. © 2015, Springer Science+Business Media New York.
引用
收藏
页数：8
相关论文
共 73 条
[11]  
Benson J.M., Et al., Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders, MAbs, 3, 6, pp. 535-545, (2011)
[12]  
Kopylov U., et al, (2014)
[13]  
Rutgeerts P., How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD?, Dig Dis, 30, 4, pp. 396-399, (2012)
[14]  
Hanauer S.B., Et al., Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial, Lancet, 359, 9317, pp. 1541-1549, (2002)
[15]  
Lichtenstein G.R., Et al., Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease, Gastroenterology, 128, 4, pp. 862-869, (2005)
[16]  
Feagan B.G., Et al., Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study, Gastroenterology, 135, 5, pp. 1493-1499, (2008)
[17]  
Colombel J.F., Et al., Infliximab, azathioprine, or combination therapy for Crohn’s disease, N Engl J Med, 362, 15, pp. 1383-1395, (2010)
[18]  
Peyrin-Biroulet L., Et al., Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease, Gut, 60, 7, pp. 930-936, (2011)
[19]  
Reinisch W., Et al., Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial, Gut, 60, 6, pp. 780-787, (2011)
[20]  
Sandborn W.J., Et al., Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, 142, 2, (2012)
12345678